The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline
Open accessAbstract
PURPOSE: To develop recommendations for management of patients with breast cancer (BC) with germline mutations in BC susceptibility genes. METHODS: The American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology convened an Expert Panel to develop recommendations based on a systematic review of the literature and a formal consensus process. RESULTS: Fifty-eight articles met eligibility criteria and formed the evidentiary basis for the local therapy recommendations; six randomized controlled trials of systemic therapy met eligibility criteria. RECOMMENDATIONS: Patients with newly diagnosed BC and BRCA1/ 2 mutations may be considered for breast-conserving therapy (BCT), with local control of the index cancer similar to that of noncarriers. The significant risk of a contralateral BC (CBC), especially in young women, and the higher risk of new cancers in the ipsilateral breast warrant discussion of bilateral mastectomy. Patients with mutations in moderate-risk genes should be offered BCT. For women with mutations in BRCA1/ 2 or moderate-penetrance genes who are eligible for mastectomy, nipple-sparing mastectomy is a reasonable approach. There is no evidence of increased toxicity or CBC events from radiation exposure in BRCA1/ 2 carriers. Radiation therapy should not be withheld in ATM carriers. For patients with germline TP53 mutations, mastectomy is advised; radiation therapy is contraindicated except in those with significant risk of locoregional recurrence. Platinum agents are recommended versus taxanes to treat advanced BC in BRCA carriers. In the adjuvant/neoadjuvant setting, data do not support the routine addition of platinum to anthracycline- and taxane-based chemotherapy. Poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and talazoparib) are preferable to nonplatinum single-agent chemotherapy for treatment of advanced BC in BRCA1/ 2 carriers. Data are insufficient to recommend PARP inhibitor use in the early setting or in moderate-penetrance carriers. Additional information available at www.asco.org/breast-cancer-guidelines .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K.-A., Mooij, T. M., Roos-Blom, M.-J., Jervis, S., van Leeuwen, F. E., Milne, R. L., Andrieu, N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7112 · Cited by 2,954
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Self-citationMeta-Analysis of BRCA1 and BRCA2 Penetrance
Chen, S., & Parmigiani, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1066 · Cited by 1,802
Syngal, S., Brand, R. E., Church, J. M., Giardiello, F. M., Hampel, H. L., & Burt, R. W. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.435 · Cited by 1,662
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
Domchek, S. M. (2010) · JAMA · doi:10.1001/jama.2010.1237 · Cited by 1,494
Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer
Hartmann, L. C., Schaid, D. J., Woods, J. E., Crotty, T. P., Myers, J. L., Arnold, P. G., Petty, P. M., Sellers, T. A., Johnson, J. L., McDonnell, S. K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400201 · Cited by 1,423
von Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., Blohmer, J. U., Jackisch, C., Paepke, S., Gerber, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70160-3 · Cited by 1,022
Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE
Mavaddat, N., Peock, S., Frost, D., Ellis, S., Platte, R., Fineberg, E., Evans, D. G., Izatt, L., Eeles, R. A., Adlard, J., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt095 · Cited by 951
Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk
Easton, D. F., Pharoah, P. D. P., Antoniou, A. C., Tischkowitz, M., Tavtigian, S. V., Nathanson, K. L., Devilee, P., Meindl, A., Couch, F. J., Southey, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmsr1501341 · Cited by 920
Self-citationSchnipper, L. E., Davidson, N. E., Wollins, D. S., Tyne, C., Blayney, D. W., Blum, D., Dicker, A. P., Ganz, P. A., Hoverman, J. R., Langdon, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.6706 · Cited by 912
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Tutt, A., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazinska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0009-7 · Cited by 912
Breast-Cancer Risk in Families with Mutations in PALB2
Antoniou, A. C., Casadei, S., Heikkinen, T., Barrowdale, D., Pylkäs, K., Roberts, J., Lee, A., Subramanian, D., De Leeneer, K., Fostira, F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400382 · Cited by 851
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W., Lin, J. C.-H., Palmisano, E., Brune, K., Jaffee, E. M., et al. (2009) · Science · doi:10.1126/science.1171202 · Cited by 826
Loibl, S., O'Shaughnessy, J., Untch, M., Sikov, W. M., Rugo, H. S., McKee, M. D., Huober, J., Golshan, M., von Minckwitz, G., Maag, D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30111-6 · Cited by 768
Efficacy of Bilateral Prophylactic Mastectomy in BRCA1 and BRCA2 Gene Mutation Carriers
Hartmann, L. C., Sellers, T. A., Schaid, D. J., Frank, T. S., Soderberg, C. L., Sitta, D. L., Frost, M. H., Grant, C. S., Donohue, J. H., Woods, J. E., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.21.1633 · Cited by 743
Lee, A., Mavaddat, N., Wilcox, A. N., Cunningham, A. P., Carver, T., Hartley, S., Babb de Villiers, C., Izquierdo, A., Simard, J., Schmidt, M. K., et al. (2019) · Genetics in Medicine · doi:10.1038/s41436-018-0406-9 · Cited by 721
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Fan, I., Tang, J., Li, S., Zhang, S., Shaw, P. A., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj465 · Cited by 680
Mavaddat, N., Barrowdale, D., Andrulis, I. L., Domchek, S. M., Eccles, D., Nevanlinna, H., Ramus, S. J., Spurdle, A., Robson, M., Sherman, M., et al. (2012) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0775 · Cited by 669
Self-citationSchnipper, L. E., Davidson, N. E., Wollins, D. S., Blayney, D. W., Dicker, A. P., Ganz, P. A., Hoverman, J. R., Langdon, R., Lyman, G. H., Meropol, N. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2518 · Cited by 655
American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
Meropol, N. J., Schrag, D., Smith, T. J., Mulvey, T. M., Langdon, R. M., Blum, D., Ubel, P. A., & Schnipper, L. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1183 · Cited by 638
Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., Olopade, O. I., Eisen, A., Weber, B., McLennan, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.033 · Cited by 621
Self-citationPatient-clinician communication: American Society of Clinical Oncology consensus guideline
Gilligan, T., Coyle, N., Frankel, R. M., Berry, D. L., Bohlke, K., Epstein, R. M., Finlay, E., Jackson, V. A., Lathan, C. S., Loprinzi, C. L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.2311 · Cited by 610
Unusual case of Smith‐Lemli‐Opitz syndrome “type II”
Seller, M. J., Russell, J., & Tint, G. S. (1995) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320560305 · Cited by 585
Gonzalez-Angulo, A. M., Timms, K. M., Liu, S., Chen, H., Litton, J. K., Potter, J., Lanchbury, J. S., Stemke-Hale, K., Hennessy, B. T., Arun, B. K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2560 · Cited by 573
Self-citationMultiple Primary Cancers in Families With Li-Fraumeni Syndrome
Hisada, M., Garber, J. E., Li, F. P., Fung, C. Y., & Fraumeni, J. F. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.8.606 · Cited by 557
Tung, N., Lin, N. U., Kidd, J., Allen, B. A., Singh, N., Wenstrup, R. J., Hartman, A.-R., Winer, E. P., & Garber, J. E. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.0747 · Cited by 556
Self-citationCancer Risks and Mortality in Heterozygous ATM Mutation Carriers
Thompson, D., Duedal, S., Kirner, J., McGuffog, L., Last, J., Reiman, A., Byrd, P., Taylor, M., & Easton, D. F. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji141 · Cited by 543
Ford, D., Easton, D. F., & Peto, J. (1995) · Europe PMC (PubMed Central) · Cited by 528
Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Dusetzina, S. B., Winn, A. N., Abel, G. A., Huskamp, H. A., & Keating, N. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.9123 · Cited by 500
ATM Mutations in Patients with Hereditary Pancreatic Cancer
Roberts, N. J., Jiao, Y., Yu, J., Kopelovich, L., Petersen, G. M., Bondy, M. L., Gallinger, S., Schwartz, A. G., Syngal, S., Cote, M. L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0194 · Cited by 491
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
Copson, E. R., Maishman, T. C., Tapper, W. J., Cutress, R. I., Greville-Heygate, S., Altman, D. G., Eccles, B., Gerty, S., Durcan, L. T., Jones, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30891-4 · Cited by 481
Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer
Ramus, S. J., Song, H., Dicks, E., Tyrer, J. P., Rosenthal, A. N., Intermaggio, M. P., Fraser, L., Gentry-Maharaj, A., Hayward, J., Philpott, S., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv214 · Cited by 437
Hahnen, E., Lederer, B., Hauke, J., Loibl, S., Kröber, S., Schneeweiss, A., Denkert, C., Fasching, P. A., Blohmer, J. U., Jackisch, C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1007 · Cited by 384
Pierce, L. J., Levin, A. M., Rebbeck, T. R., Ben-David, M. A., Friedman, E., Solin, L. J., Harris, E. E., Gaffney, D. K., Haffty, B. G., Dawson, L. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7888 · Cited by 340
Self-citationLaDuca, H., Stuenkel, A. J., Dolinsky, J. S., Keiles, S., Tandy, S., Pesaran, T., Chen, E., Gau, C.-L., Palmaer, E., Shoaepour, K., et al. (2014) · Genetics in Medicine · doi:10.1038/gim.2014.40 · Cited by 332
Frost, M. H. (2000) · JAMA · doi:10.1001/jama.284.3.319 · Cited by 325
Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
Graeser, M. K., Engel, C., Rhiem, K., Gadzicki, D., Bick, U., Kast, K., Froster, U. G., Schlehe, B., Bechtold, A., Arnold, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9430 · Cited by 314
Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status
Haffty, B. G., Harrold, E., Khan, A. J., Pathare, P., Smith, T. E., Turner, B. C., Glazer, P. M., Ward, B., Carter, D., Matloff, E., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08434-9 · Cited by 307
Metcalfe, K., Gershman, S., Ghadirian, P., Lynch, H. T., Snyder, C., Tung, N., Kim-Sing, C., Eisen, A., Foulkes, W. D., Rosen, B., et al. (2014) · BMJ · doi:10.1136/bmj.g226 · Cited by 305
Self-citationvan Sprundel, T. C., Schmidt, M. K., Rookus, M. A., Brohet, R., van Asperen, C. J., Rutgers, E. J. T., van‘t Veer, L. J., & Tollenaar, R. A. E. M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602703 · Cited by 291
Pierce, L. J., Strawderman, M., Narod, S. A., Oliviotto, I., Eisen, A., Dawson, L., Gaffney, D., Solin, L. J., Nixon, A., Garber, J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.19.3360 · Cited by 268
Self-citationEffect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis
Baretta, Z., Mocellin, S., Goldin, E., Olopade, O. I., & Huo, D. (2016) · Medicine · doi:10.1097/md.0000000000004975 · Cited by 260
The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer
Hartmann, L. C., & Lindor, N. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1503523 · Cited by 253
Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions
Streeter, S. B., Schwartzberg, L., Husain, N., & Johnsrud, M. (2011) · Journal of Oncology Practice · doi:10.1200/jop.2011.000316 · Cited by 248
Li, X., You, R., Wang, X., Liu, C., Xu, Z., Zhou, J., Yu, B., Xu, T., Cai, H., & Zou, Q. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1465 · Cited by 234
Brekelmans, C. T. M., Tilanus-Linthorst, M. M. A., Seynaeve, C., vd Ouweland, A., Menke-Pluymers, M. B. E., Bartels, C. C. M., Kriege, M., van Geel, A. N., Burger, C. W., Eggermont, A. M. M., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.12.009 · Cited by 233 · cited 1×
“While studies regarding the prognosis of breast cancer for BRCA1/2 mutation carriers compared with noncarriers have yielded inconsistent results, the weight of evidence suggests that, after adjusting for known prognostic factors, prognosis is the same for carriers and noncarriers.(68,100,101) A British prospective stu…”
ResultPredictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
Metcalfe, K., Gershman, S., Lynch, H. T., Ghadirian, P., Tung, N., Kim-Sing, C., Olopade, O. I., Domchek, S., McLennan, J., Eisen, A., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.120 · Cited by 232
Self-citationHeemskerk‐Gerritsen, B. A. M., Rookus, M. A., Aalfs, C. M., Ausems, M. G. E. M., Collée, J. M., Jansen, L., Kets, C. M., Keymeulen, K. B. M. I., Koppert, L. B., Meijers‐Heijboer, H. E. J., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29032 · Cited by 216
Heymann, S., Delaloge, S., Rahal, A., Caron, O., Frebourg, T., Barreau, L., Pachet, C., Mathieu, M.-C., Marsiglia, H., & Bourgier, C. (2010) · Radiation Oncology · doi:10.1186/1748-717x-5-104 · Cited by 213
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS
Southey, M. C., Goldgar, D. E., Winqvist, R., Pylkäs, K., Couch, F., Tischkowitz, M., Foulkes, W. D., Dennis, J., Michailidou, K., van Rensburg, E. J., et al. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-103839 · Cited by 213
BRCA in breast cancer: ESMO Clinical Practice Guidelines
Balmaña, J., Diez, O., Rubio, I., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq161 · Cited by 205
Sharma, P., Klemp, J. R., Kimler, B. F., Mahnken, J. D., Geier, L. J., Khan, Q. J., Elia, M., Connor, C. S., McGinness, M. K., Mammen, J. M. W., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2980-0 · Cited by 201
Pierce, L. J., Phillips, K.-A., Griffith, K. A., Buys, S., Gaffney, D. K., Moran, M. S., Haffty, B. G., Ben-David, M., Kaufman, B., Garber, J. E., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0894-z · Cited by 199
Self-citationHan, H. S., Diéras, V., Robson, M., Palácová, M., Marcom, P. K., Jager, A., Bondarenko, I., Citrin, D., Campone, M., Telli, M. L., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx505 · Cited by 194
Self-citationLoblaw, D. A., Prestrud, A. A., Somerfield, M. R., Oliver, T. K., Brouwers, M. C., Nam, R. K., Lyman, G. H., & Basch, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0489 · Cited by 189
Self-citationLong-term results of screening with magnetic resonance imaging in women with BRCA mutations
Passaperuma, K., Warner, E., Causer, P. A., Hill, K. A., Messner, S., Wong, J. W., Jong, R. A., Wright, F. C., Yaffe, M. J., Ramsay, E. A., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.204 · Cited by 183
Weischer, M., Nordestgaard, B. G., Pharoah, P., Bolla, M. K., Nevanlinna, H., van't Veer, L. J., Garcia-Closas, M., Hopper, J. L., Hall, P., Andrulis, I. L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7336 · Cited by 181
Boughey, J. C., Attai, D. J., Chen, S. L., Cody, H. S., Dietz, J. R., Feldman, S. M., Greenberg, C. C., Kass, R. B., Landercasper, J., Lemaine, V., et al. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5443-5 · Cited by 181
Self-citationJakub, J. W., Peled, A. W., Gray, R. J., Greenup, R. A., Kiluk, J. V., Sacchini, V., McLaughlin, S. A., Tchou, J. C., Vierkant, R. A., Degnim, A. C., et al. (2018) · JAMA Surgery · doi:10.1001/jamasurg.2017.3422 · Cited by 181
Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer
Evans, D. G. R., Ingham, S. L., Baildam, A., Ross, G. L., Lalloo, F., Buchan, I., & Howell, A. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2583-1 · Cited by 178 · cited 1×
“Six studies evaluated the efficacy of contralateral prophylactic mastectomy on OS outcomes in BRCA1/2 mutation carriers with breast cancer.(18,36,41,43-45) Evans et al(36) investigated whether contralateral risk-reducing mastectomy improved survival in a series of women with unilateral breast cancer and BRCA1/2 mutati…”
BackgroundLu, H.-M., Li, S., Black, M. H., Lee, S., Hoiness, R., Wu, S., Mu, W., Huether, R., Chen, J., Sridhar, S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2956 · Cited by 178
Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Phillips, K.-A., Milne, R. L., Rookus, M. A., Daly, M. B., Antoniou, A. C., Peock, S., Frost, D., Easton, D. F., Ellis, S., Friedlander, M. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.8313 · Cited by 171
Goodwin, P. J., Phillips, K.-A., West, D. W., Ennis, M., Hopper, J. L., John, E. M., O'Malley, F. P., Milne, R. L., Andrulis, I. L., Friedlander, M. L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.0068 · Cited by 167
Iannuzzi, C. M., Atencio, D. P., Green, S., Stock, R. G., & Rosenstein, B. S. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)02684-0 · Cited by 159
Heikkinen, T., Kärkkäinen, H., Aaltonen, K., Milne, R. L., Heikkilä, P., Aittomäki, K., BLOMQVIST, C. P., & Nevanlinna, H. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3128 · Cited by 158
Robson, M., Levin, D., Federici, M., Satagopan, J., Bogolminy, F., Heerdt, A., Borgen, P., McCormick, B., Hudis, C., Norton, L., et al. (1999) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/91.24.2112 · Cited by 158
Self-citationTwo metachronous tumors in the radiotherapy fields of a patient with Li‐Fraumeni syndrome
Limacher, J., Frébourg, T., Natarajan‐Amé, S., & Bergerat, J. (2001) · International Journal of Cancer · doi:10.1002/ijc.1021 · Cited by 151
Bernstein, J. L., Haile, R. W., Stovall, M., Boice, J. D., Shore, R. E., Langholz, B. M., Thomas, D. C., Bernstein, L., Lynch, C. F., Olsen, J. H., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq055 · Cited by 151
SEOM clinical guidelines in Hereditary Breast and ovarian cancer
On behalf of the SEOM Hereditary Cancer Working Group, Llort, G., Chirivella, I., Morales, R., Serrano, R., Sánchez, A. B., Teulé, À., Lastra, E., Brunet, J., Balmañà, J., et al. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1435-3 · Cited by 135
Larsen, M. J., Kruse, T. A., Tan, Q., Lænkholm, A., Bak, M., Lykkesfeldt, A. E., Sørensen, K. P., Hansen, T. V. O., Ejlertsen, B., Gerdes, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064268 · Cited by 133
The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers
Weigelt, B., Bi, R., Kumar, R., Blecua, P., Mandelker, D. L., Geyer, F. C., Pareja, F., James, P. A., kConFab Investigators, Couch, F. J., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy028 · Cited by 128
Self-citationSchmidt, M. K., Tollenaar, R. A. �. �., Kemp, S. R. M., Broeks, A., Cornelisse, C. J., Smit, V. T. H. B. M., Peterse, J. L., van Leeuwen, F. E., & Veer, L. V. ‘. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3024 · Cited by 121
Turner, B. C., Harrold, E., Matloff, E., Smith, T., GUMBS, A., Beinfield, M., Ward, B., Skolnick, M., Glazer, P., Thomas, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3017 · Cited by 118
Frost, M. H., Hoskin, T. L., Hartmann, L. C., Degnim, A. C., Johnson, J. L., & Boughey, J. C. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1917-7 · Cited by 113
Self-citationKaas, R., Verhoef, S., Wesseling, J., Rookus, M. A., Oldenburg, H. S. A., Peeters, M.-J. T. F. D. V., & Rutgers, E. J. T. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181c3c36d · Cited by 109
Andreassen, C. N., Overgaard, J., Alsner, J., Overgaard, M., Herskind, C., Cesaretti, J. A., Atencio, D. P., Green, S., Formenti, S. C., Stock, R. G., et al. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.09.014 · Cited by 106
Kirova, Y. M., Savignoni, A., Sigal-Zafrani, B., de La Rochefordiere, A., Salmon, R. J., This, P., Asselain, B., Stoppa-Lyonnet, D., & Fourquet, A. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0685-6 · Cited by 102
Breast-Conserving Surgery in BRCA1/2 Mutation Carriers: Are We Approaching an Answer?
Garcia-Etienne, C. A., Barile, M., Gentilini, O. D., Botteri, E., Rotmensz, N., Sagona, A., Farante, G., Galimberti, V., Luini, A., Veronesi, P., et al. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0638-7 · Cited by 100
The Effect of CHEK2 Variant I157T on Cancer Susceptibility: Evidence from a Meta-Analysis
Han, F., Guo, C., & Liu, L. (2013) · DNA and Cell Biology · doi:10.1089/dna.2013.1970 · Cited by 98
Decker, B. J., Allen, J., Luccarini, C., Pooley, K. A., Shah, M., Bolla, M. K., Wang, Q., Ahmed, S., Baynes, C., Conroy, D. M., et al. (2017) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2017-104588 · Cited by 94
Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy
Seynaeve, C., Verhoog, L. C., van de Bosch, L. M. C., van Geel, A. N., Menke-Pluymers, M., Meijers-Heijboer, E. J., van den Ouweland, A. M. W., Wagner, A., Creutzberg, C. L., Niermeijer, M. F., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.017 · Cited by 93
Broeks, A., Braaf, L. M., Huseinovic, A., Nooijen, A., Urbanus, J. H. M., Hogervorst, F. B. L., Schmidt, M. K., Klijn, J. G. M., Russell, N. S., van Leeuwen, F. E., et al. (2007) · Breast Cancer Research · doi:10.1186/bcr1668 · Cited by 89
Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers
Metcalfe, K. A., Lynch, H. T., Ghadirian, P., Tung, N., Kim‐Sing, C., Olopade, O. I., Domchek, S. M., Eisen, A. F., Foulkes, W. D., Rosen, B. P., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1336-7 · Cited by 88
Self-citationBreast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women
Schmidt, M. K., van den Broek, A. J., Tollenaar, R. A. �. �., Smit, V. T. H. B. M., Westenend, P. J., Brinkhuis, M., Oosterhuis, W., Wesseling, J., Janssen-Heijnen, M. L. G., Jobsen, J. J., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw329 · Cited by 87
Nipple-sparing mastectomy in patients withBRCA1/2mutations and variants of uncertain significance
Manning, A. T., Wood, C., Eaton, A. A., Stempel, M. M., Capko, D. M., Pusic, A. L., Morrow, M., & Sacchini, V. (2015) · British journal of surgery · doi:10.1002/bjs.9884 · Cited by 85
Kriege, M., Hollestelle, A., Jager, A., Huijts, P. E. A., Berns, E., Sieuwerts, A. M., Gelder, M. E. M., Collée, J. M., Devilee, P., Hooning, M. J., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.306 · Cited by 82
Bernstein, J. L., Thomas, D. C., Shore, R. E., Robson, M. E., Boice, J. D., Stovall, M. A., Andersson, M., Bernstein, L., Malone, K. E., Reiner, A. S., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.04.028 · Cited by 81
Self-citationSalmón, A. S., Amikam, D., Sodha, N., Davidson, S., Basel‐Vanagaite, L., Eeles, R. A., Abeliovich, D., & Peretz, T. (2007) · Clinical Oncology · doi:10.1016/j.clon.2007.05.001 · Cited by 80
Excess Risk for Contralateral Breast Cancer in CHEK2*1100delC Germline Mutation Carriers
Broeks, A., de Witte, L. D., Nooijen, A., Huseinovic, A., Klijn, J. G. M., van Leeuwen, F. E., Russell, N. S., & Veer, L. J. V. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000010697.49896.03 · Cited by 80
Shanley, S., McReynolds, K. M., Ardern-Jones, A. T., A’Hern, R., Fernando, I. N., Yarnold, J. R., Evans, D. G., Eccles, D., Hodgson, S. V., Ashley, S. E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1244 · Cited by 75
Self-citationHereditary Cancer Syndromes—A Primer on Diagnosis and Management
Samadder, N. J., Giridhar, K. V., Baffy, N. J., Riegert‐Johnson, D. L., & Couch, F. J. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.02.017 · Cited by 75
Patient-Reported Outcomes After Choice for Contralateral Prophylactic Mastectomy
Hwang, E. S., Locklear, T., Rushing, C. N., Samsa, G., Abernethy, A. P., Hyslop, T., & Atisha, D. M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.5427 · Cited by 70
Vangala, D., Cauchin, E., Balmañà, J., Wyrwicz, L. S., Cutsem, E. V., Güller, U., Castells, A., Carneiro, F., Hammel, P. R., Ducreux, M. P., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.004 · Cited by 68
Bremer, M., Klöpper, K., Yamini, P., Bendix, R., Dörk, T., & Karstens, J. H. (2003) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2003.08.004 · Cited by 66
Shah, P. D., Patil, S. N., Dickler, M. N., Offit, K., Hudis, C. A., & Robson, M. E. (2016) · Cancer · doi:10.1002/cncr.29903 · Cited by 62
Self-citationFrequency of the CHEK2 1100delC Mutation among Women with Breast Cancer: An International Study
Zhang, S., Phelan, C. M., Zhang, P., Rousseau, F., Ghadirian, P., Robidoux, A., Foulkes, W. D., Hamel, N., McCready, D. R., Trudeau, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5187 · Cited by 61
van den Broek, A. J., Schmidt, M. K., Veer, L. V. ‘., Oldenburg, H. S. A., Rutgers, E. J. T., Russell, N. S., Smit, V. T. H. B. M., Voogd, A. C., Koppert, L. B., Siesling, S., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002804 · Cited by 60
Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer
Rummel, S. K., Varner, E. L., Shriver, C. D., & Ellsworth, R. E. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2348-2 · Cited by 57
Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer
Warner, E. (2018) · Cancers · doi:10.3390/cancers10120477 · Cited by 57
High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer
Nilsson, M. P., Hartman, L., Kristoffersson, U., Johannsson, O. T., Borg, Å., Henriksson, K., Lanke, E., Olsson, H., & Loman, N. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3115-3 · Cited by 56
Fletcher, O., Johnson, N., dos‐Santos‐Silva, I., Kilpivaara, O., Aittomäki, K., BLOMQVIST, C. P., Nevanlinna, H. A., Wasielewski, M., Meijers-Heijboer, H. E. J., Broeks, A., et al. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0416 · Cited by 55
Su, Y., & Swift, M. (2001) · JAMA · doi:10.1001/jama.286.18.2233 · Cited by 53
The WECARE Study Collaborative Group, Mellemkjær, L., Dahl, C., Olsen, J. H., Bertelsen, L., Guldberg, P., Christensen, J., Børresen-Dale, A.-L., Stovall, M. A., Langholz, B. M., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604228 · Cited by 51
ATM, radiation, and the risk of second primary breast cancer
Bernstein, J. L., WECARE Study Collaborative Group, & Concannon, P. (2017) · International Journal of Radiation Biology · doi:10.1080/09553002.2017.1344363 · Cited by 50
Variants in the ATM Gene Associated with a Reduced Risk of Contralateral Breast Cancer
CONCANNON, P. J., Haile, R. W., Børresen‐Dale, A., Rosenstein, B. S., Gatti, R. A., Teraoka, S. N., Diep, A. T., Jansen, L., Atencio, D. P., Langholz, B. M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0134 · Cited by 48
Drooger, J. C., Akdeniz, D., Pignol, J., Koppert, L. B., McCool, D., Seynaeve, C., Hooning, M. J., & Jager, A. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3597-7 · Cited by 39
Grant, R. C., Al-Sukhni, W., Borgida, A., Holter, S., Kanji, Z. S., McPherson, T. A., Whelan, E. R., Serra, S., Trinh, Q. M., Peltekova, V. D., et al. (2013) · Human Genomics · doi:10.1186/1479-7364-7-11 · Cited by 37
Meyer, A. A., Dörk, T., Sohn, C., Karstens, J. H., & Bremer, M. (2007) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2006.12.002 · Cited by 36
Henry, E., Villalobos, V. M., Million, L., Jensen, K. C., West, R. B., Ganjoo, K. N., Lebensohn, A., Ford, J. M., & Telli, M. L. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0097 · Cited by 35
The spectrum of ATM missense variants and their contribution to contralateral breast cancer
Broeks, A., Braaf, L. M., Huseinovic, A., Schmidt, M. K., Russell, N. S., van Leeuwen, F. E., Hogervorst, F. B. L., & Veer, L. V. ‘. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9543-6 · Cited by 35
Grobmyer, S. R., Pederson, H. J., Valente, S. A., Al‐Hilli, Z., Radford, D. M., Djohan, R. S., Yetman, R. J., Eng, C., & Crowe, J. P. (2018) · BJS Open · doi:10.1002/bjs5.50117 · Cited by 35
Cao, W., Xie, Y., He, Y., Li, J., Wang, T., Fan, Z., Fan, T., & Ouyang, T. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05199-8 · Cited by 26
Ferrarini, A., Auteri-Kaczmarek, A., Pica, A., Boesch, N., Heinimann, K., Schäfer, S. C., Mégalo, S. V., Cina, V., Beckmann, J. S., & Monnerat, C. (2011) · Familial Cancer · doi:10.1007/s10689-010-9415-9 · Cited by 25
Clinical and molecular characterization ofBRCA-associated breast cancer: results from the DBCG
Sønderstrup, I. M. H., Lænkholm, A., Jensen, M., Eriksen, J. O., Gerdes, A., Hansen, T. V. O., Kruse, T. A., Larsen, M. J., Pedersen, I. S., Rossing, M., et al. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1398415 · Cited by 25
Hallam, S., Govindarajulu, S., Huckett, B., & Bahl, A. K. (2015) · Clinical Oncology · doi:10.1016/j.clon.2015.06.001 · Cited by 21
Yang, Z., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., Zhang, J., & Xie, Y. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-05124-5 · Cited by 20
Cited by
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
Cortesi, L., Rugo, H. S., & Jackisch, C. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00796-4 · Cited by 393
Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer
Burstein, H. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1307118 · Cited by 316
Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline
Bedrosian, I., Somerfield, M. R., Achatz, M. I., Boughey, J. C., Curigliano, G., Friedman, S., Kohlmann, W. K., Kurian, A. W., Laronga, C., Lynce, F., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02225 · Cited by 216
Self-citationMolecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer
Gu, Y., Yang, R., Zhang, Y., Guo, M., Takehiro, K., Zhan, M., Yang, L., & Wang, H. (2025) · Molecular Biomedicine · doi:10.1186/s43556-024-00239-2 · Cited by 184
Siglen, E., Vetti, H. H., Lunde, A. B. F., Hatlebrekke, T. A., Strømsvik, N., Hamang, A., Hovland, S. T., Rettberg, J. W., Steen, V. M., & Bjorvatn, C. (2022) · Patient Education and Counseling · doi:10.1016/j.pec.2021.09.027 · Cited by 91
Metadata
- Authors
- Tung, N. M., Boughey, J. C., Pierce, L. J., Robson, M. E., Bedrosian, I., Dietz, J. R., Dragun, A., Gelpi, J. B., Hofstatter, E. W., Isaacs, C. J., Jatoi, I., Kennedy, E., Litton, J. K., Mayr, N. A., Qamar, R. D., Trombetta, M. G., Harvey, B. E., Somerfield, M. R., & Zakalik, D.
- Venue
- Journal of Clinical Oncology
- Published
- 2020-06-20
- Volume
- 38
- Issue
- 18
- Pages
- 2080-2106
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3014383023
- Cited by
- 332
- References
- 119
- FWCI
- 24.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.